Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Abstracts

Clinical pathology selected abstracts

August 2025—The Accreditation Council for Graduate Medical Education (ACGME) oversees graduate medical education and closely monitors resident wellness. In 2017, the ACGME published findings from a national study outlining the causes of death among residents and fellows from 2000 through 2014. The most common overall cause of death was malignant neoplasm, and it was the leading cause of death among female residents and fellows. Suicide was the leading cause of death for male residents and the second leading cause for females. Twenty-three percent of deaths by suicide occurred in the first academic quarter of trainees’ first year in their medical programs.

Anatomic pathology selected abstracts

August 2025—Certain subtypes of colorectal carcinoma pose diagnostic challenges in daily practice due to sometimes overlapping morphologic and immunohistochemical features and are associated with worse prognoses than poorly differentiated adenocarcinoma not otherwise specified (PDA-NOS). Other variants of poorly differentiated colon cancers with solid growth patterns that have, anecdotally, been recognized as posing diagnostic challenges include large cell neuroendocrine carcinoma (LCNEC), medullary carcinoma (MC), undifferentiated carcinoma (UC), and lymphoepithelioma-like carcinoma (LELC). The authors conducted a study to determine survival outcomes between patients with poorly differentiated adenocarcinoma and those with a variant carcinoma morphology that may affect prognosis. They also analyzed interobserver agreement among gastrointestinal pathologists at their institution in subclassifying poorly differentiated colorectal carcinoma. All consecutive patients with diagnoses of PDA-NOS, MC, LCNEC, UC, and LELC between July 2018 and July 2023 were included.

Molecular pathology selected abstracts

August 2025—Childhood malignancies such as Wilms tumor—the most common type of kidney cancer in children—exhibit very few DNA changes when tested by traditional sequencing methods. Some of these types of tumors have fewer genetic anomalies than age-matched normal tissue. This raises the question, How can such genetically “quiet” malignancies emerge and progress without conventional driver mutations? To address this question, the authors employed high-resolution, ultra-deep sequencing to determine if hypomutation in juvenile kidney cancers characterized by a paucity of mutations, specifically Wilms tumor, is genuine or an artifact of conventional analytical constraints. By applying high-resolution duplex sequencing (Nanoseq) to Wilms tumors and matched normal kidneys from six pediatric patients, including four infants and two school-age children, the authors showed that standard bulk whole genome sequencing significantly underestimates the mutational burden in tumors from infants.

Clinical pathology selected abstracts

July 2025—A large number of cancers remain undetected until later stages, including lung, colorectal, cervical, ovarian, pancreatic, and prostate cancers. The U.S. Preventive Services Task Force recommends screening based on age and other risk factors. It is estimated that more than 4 million cancers have been avoided due to early screening methods. Efforts are being made to develop cancer-screening tests that are easier to perform and less invasive and that detect multiple types of cancer, with the intent of reducing cancer-related morbidity and mortality. Multicancer early detection (MCED) assays depend on circulating cell-free DNA to detect a shared single cancer signal.

Anatomic pathology selected abstracts

July 2025—Intraductal oncocytic papillary neoplasm of the pancreas is a recently recognized pancreatic tumor. The authors conducted a study to generate a comprehensive and quantitative summary of various aspects of intraductal oncocytic papillary neoplasms (IOPN). They searched the PubMed, Scopus, and Embase databases for studies reporting on pancreatic IOPN. Clinicopathologic, immunohistochemical, and molecular data were extracted from the studies and summarized. A comparative analysis of the molecular alterations of IOPN in juxtaposition with the typical molecular profile of conventional pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm from reference cohorts was subsequently conducted.

Molecular pathology selected abstracts

July 2025—Liver damage can result in a build up of scar tissue, or fibrosis, a hallmark of chronic liver disease (CLD). The latter has been attributed to a variety of risk factors, including viruses (primarily hepatitis B and C), obesity, and alcohol abuse. Furthermore, some patients have a genetic predisposition for the disease. Alpha-1 antitrypsin (A1AT) deficiency and hereditary hemochromatosis are two such inherited disorders that cause hepatocyte stress and damage. In A1AT deficiency, mutations in the SERPINA1 gene produce abnormal variants of the A1AT protein, which can accumulate in the liver and lead to hepatocyte damage. Mutations in the HFE gene are responsible for hereditary hemochromatosis.

Pathology informatics selected abstracts

July 2025—Computational pathology has largely focused on analyzing tissue slides and overlooked worthwhile information in gross images. Recognizing this, the authors introduced a novel deep learning model based on Swin Transformer architecture and called Swin Transformer-based Gross Features Detective Network (SGFD-network). They sought to summarize and classify the gross examination characteristics of ovarian epithelial tumors by analyzing images of gross specimens using this deep learning approach. The SGFD-network is especially useful for distinguishing borderline tumors with microinvasive components from frank carcinomas. This capability is crucial during frozen section analysis, in which limited sampling and time pressures often challenge diagnostic accuracy.

Clinical pathology selected abstracts

June 2025—Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist medication that has FDA approval for treating diabetes and obesity and that has shown exceptional efficacy. A rapid increase in use of this drug has been accompanied by reports of reduced alcohol use and cravings during semaglutide treatment. Alcohol use is a leading modifiable cause of morbidity and mortality and accounts for four to five percent of disease burden and 2.6 million deaths per year globally. Alcohol is also associated with increased risk of common diseases, including cardiovascular and liver disease and cancers. It is estimated that approximately 29 and 11 percent of U.S. adults meet lifetime and past-year criteria for alcohol use disorder (AUD), respectively.

Anatomic pathology selected abstracts

June 2025—Transbronchial cryobiopsies are increasingly used to diagnose interstitial lung disease, but published information on the features of specific manifestations of ILD in cryobiopsies is lacking. Therefore, the authors sought to provide pathologic guidelines for separating usual interstitial pneumonia (UIP) of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP), and connective tissue disease-associated interstitial lung disease (CTD-ILD) in cryobiopsies. They examined 120 cryobiopsies from patients with CTD-ILD established via multidisciplinary discussion and compared them with a prior series of 121 biopsies from patients with IPF or FHP also established via multidisciplinary discussion. A nonspecific interstitial pneumonia (NSIP) pattern alone was seen in 36 of 120 (30 percent) CTD-ILD, three of 83 (3.6 percent) FHP, and two of 38 (5.2 percent) IPF cases, statistically favoring a diagnosis of CTD-ILD.

Molecular pathology selected abstracts

June 2025—Comprehensive molecular profiling and DNA methylation classification have become critical for diagnosing and managing central nervous system tumors. However, workflows for molecular testing of these tumors are often limited by the cost of equipment and reagents, technical complexity, and lengthy turnaround times. The wide range of alterations that can be present, including MGMT promoter methylation, single nucleotide variants, insertions or deletions (indels), copy number variants, and fusions and structural variants, often necessitate the use of multiple assays for a complete molecular workup. All of these factors have led to a growing demand for molecular assays that are faster, more comprehensive, and more accessible. Recognizing this need, the authors had previously conducted a proof-of-concept study of an adaptive sampling-based nanopore sequencing workflow platform, called Rapid-CNS2, that they had developed.

MARKETPLACE

TRENDING